Search Results - "McIntyre, Debra AG"

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab by Ricciuti, Biagio, Elkrief, Arielle, Lin, Jessica, Zhang, Jianjun, Alessi, Joao V., Lamberti, Giuseppe, Gandhi, Malini, Di Federico, Alessandro, Pecci, Federica, Wang, Xinan, Makarem, Maisam, Hidalgo Filho, Cassio Murilo, Gorria, Teresa, Saini, Arushi, Pabon, Cindy, Lindsay, James, Pfaff, Kathleen L., Welsh, Emma L., Nishino, Mizuki, Sholl, Lynette M., Rodig, Scott, Kilickap, Saadettin, Rietschel, Petra, McIntyre, Debra AG, Pouliot, Jean-Francois, Altan, Mehmet, Gainor, Justin F., Heymach, John V., Schoenfeld, Adam J., Awad, Mark M.

“…Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor…”
Get full text

Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT) by Smithy, James William, Kalvin, Hannah L, Raber, Vladislav, Maher, Colleen Anne, Kleman, Jenna, McIntyre, Debra AG, Shoushtari, Alexander Noor, Betof Warner, Allison, Callahan, Margaret K., Momtaz, Parisa, Eton, Omar, Nair, Suresh, Wolchok, Jedd D., Chapman, Paul B., Panageas, Katherine, Postow, Michael A.

“…9517 Background: Initial results from ADAPT-IT (NCT03122522) demonstrated that adaptive dosing of nivolumab (nivo) and ipilimumab (ipi) based on early…”
Get full text

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials by Murray, Joseph Christopher, McIntyre, Debra AG, Anagnostou, Valsamo, Brahmer, Julie R., Meisel, Alexander, Sezer, Ahmet, Gogishvili, Miranda, Melkadze, Tamar, Baramidze, Ana, Makharadze, Tamta, He, Adam, Li, Siyu, Jankovic, Vladimir, Seebach, Frank A., Rietschel, Petra, Kim, Young J., Gullo, Giuseppe, Pouliot, Jean-Francois

“…9028 Background: Circulating innate and adaptive immune cells can modulate clinical responses to immune checkpoint inhibition in pts with cancer; however,…”
Get full text

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial by Baramidze, Ana, Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, AG McIntyre, Debra, Perez, Javier, Kaul, Manika, Quek, Ruben G.W., Seebach, Frank, Rietschel, Petra, Pouliot, Jean-Francois

“…•PD-L1 expression guides NSCLC treatment and regulatory approvals.•Study highlights efficacy of cemiplimab plus chemotherapy in PD-L1 ≥ 1 % population.•We…”
Get full text